A high rate of symptomatic spinal pseudoarthrosis and a wide range of complications associated with the use of iliac crest bone graft (the gold standard) have prompted the spine surgery community to seek alternative options to promote spinal fusion. Emory University has been one of the global leaders in this endeavor. This invited review covers the last 25 years of Emory's contributions to translational spine research, focusing specifically on our work with bone morphogenetic proteins (BMP) and the BMP signaling pathway. As a result of this work, recombinant human BMP-2 is the only Food and Drug Administration approved biologic bone graft substitute. It has been shown to significantly increase spinal fusion rates across the spinal column because of its potent ability to stimulate local bone formation through the recruitment of mesenchymal stem cells. This review covers our development of animal models of spinal fusion, our body of work regarding the translation of BMP from the benchtop to the clinic, the discovery of LMP-1 and strategies to enhance cellular responsiveness to BMPs, and the design of various small molecule drugs that can enhance local bone formation.
Since the introduction of spinal arthrodesis surgery in 1911, it has become a commonly used procedure for the treatment of multiple spinal conditions across the cervical, thoracic, and lumbar spine. Despite state-of-the-art spinal instrumentation and techniques, failure of spinal fusion (pseudarthrosis) is still unfortunately a common complication, with a rate in primary fusions as high as 20% 1) . In addition, almost one-quarter of all revision arthrodesis surgeries are performed for a pseudarthrosis 2) . Clinically, patients with a pseudarthrosis often report much poorer outcomes (23% positive outcome) compared with those in whom a solid fusion was achieved (81%) 3) . In addition, the high cost required to continue to treat spinal pseudarthrosis represents a major burden on the global healthcare system 4) . The current "gold standard" bone graft for spinal fusion remains autologous iliac crest bone graft (ICBG), but its harvest is associated with long-term donor site pain in up to 25% of patients 5, 6) . Moreover, ICBG itself has a pseudarthrosis rate nearing 40% in the posterolateral spine in primary arthrodesis procedures and up to 60% in revisions 7, 8) . Although a variety of alternative bone graft options are available (i.e., bone allograft and demineralized bone matrix), none have proven to be suitable and effective substitutes for ICBG 9) . The high rate of pseudarthrosis and the lack of viable alternatives for ICBG have motivated the scientific community to expand research efforts into biologic bone graft substitutes. Marshall Urist in 1965 first popularized the notion that bone matrix itself contains proteins capable of osteoinduction (ability to directly induce bone formation). Dr. Urist dedicated his entire research career to purifying, identifying, and characterizing these proteins, which he named bone morphogenetic proteins (BMP) 10, 11) . Although over 20 types of BMP have since been described, only some of the BMPs are osteoinductive: BMP-2, BMP-6, and BMP-9 12) . The most widely studied recombinant growth factor for the use in spine surgery is recombinant human (rh) BMP-2. Since gaining Food and Drug Administration (FDA) approval in the United States for anterior lumbar interbody fusions (ALIFs) in 2002 (Infuse , Medtronic), rhBMP-2 is widely considered a critical addition to the armamentarium that the surgeon has at their disposal to enhance spinal fusion rates.
In fact, because multiple studies have indicated that patients receiving rhBMP-2 achieve solid fusions without major adverse events, it has been reported to be used in an "offlabel" fashion in more than 85% of all spinal fusion cases across the entire spinal column.
Although many labs around the world have contributed significantly to our understanding of BMP in the setting of spinal fusion, Emory University has been at the forefront of translational spine fusion and BMP research for over 25 years. The purpose of this invited review is to highlight our work and experience in this exciting arena. We have divided this research into four discreet categories, each reviewed below.
I. Development of Animal Models for Spinal Fusion
In 1995, Dr. Scott Boden of Emory University developed and validated the first preclinical model of lumbar intertransverse process spinal fusion 13) . Up to this point, all previous animal models of spinal fusion had not replicated the surgical technique, the mechanical environment, the biology of graft incorporation, or the pseudarthrosis rate that is found in humans. Once the model was developed, it served as a much-needed tool that became critical in gaining a basic understanding of the biology of spinal fusion as well as allowing the testing of biologic fusion enhancement by entities such as cytokines, growth factors, and hormones. Although much was known at that point about the biology of fracture repair, surprisingly little was understood about the biology of posterolateral spinal fusions. It was reasoned that a more fundamental approach to solving the spinal pseudarthrosis problem would lie in experiments designed to illuminate the sequences of events, at a cellular level, involved in the spine fusion process. In other words, the problem had to first be understood in order to solve it.
Later that year, in a series of papers, Boden et al. 14, 15) used their animal model of intertransverse spinal fusion for just that purpose. In the first of two papers 14) , the authors characterized the healing sequence of a developing intertransverse spine fusion using autologous ICBG from a temporal and spatial standpoint using sequential histology. Three distinct phases of healing (inflammatory, reparative, and remodeling) were reported. Membranous bone formation, evident first at the ends of the fusion emanating from the decorticated transverse processes, was the predominant mechanism of healing. The central zone, however, was somewhat different in that there was a period of endochondral bone formation, where cartilage formed first but was subsequently converted to bone only in successful fusions. The authors concluded that the persistence of a central cartilage zone may possibly be related to some types of pseudarthroses.
Next, Boden and colleagues 15) determined the minimum effective dose of a bovine-derived osteoinductive bone protein extract (known to contain BMPs) for intertransverse process lumbar fusion in both rabbits and nonhuman primates. The authors reported that there was a dose-dependent response to the osteoinductive growth factors when used in rabbits and rhesus monkeys. The authors found that there was a dose threshold for locally delivered growth factors that must be overcome before bone formation is consistently induced.
A few years later, Morone et al. 16) followed up those studies with another set of experiments in rabbits in which the authors determined: (1) the temporal and spatial pattern of gene expression within the healing fusion mass following posterolateral intertransverse arthrodesis using ICBG and (2) how the addition of locally delivered rhBMP-2 to ICBG affected the gene expression pattern within the developing spine fusion mass. This study provided the first evidence that a reproducible temporal sequence and spatial pattern of gene expression exists in healing spine fusions. Interestingly, the authors found a temporal lag in gene expression in the central portion of the fusion mass that paralleled the lag in healing within the central zone that had previously been observed in histologic studies 14) . The addition of rhBMP-2 resulted in an increase in the early expression of BMP-6, which was subsequently associated with the expression of higher levels of type I collagen, osteocalcin, and other important bone-related genes. The authors concluded that rhBMP-2 may have the potential to decrease the likelihood of a pseudarthrosis by increasing the level of bone-related gene expression throughout the fusion mass and eliminating the delay in endochondral healing within the central zone.
These landmark studies represented an essential building block in our understanding of the biology of spinal fusion and showed the potential for the use of osteoinductive growth factors like rhBMP-2 to enhance posterolateral intertransverse process spinal fusions. For the first time, experiments could be designed in which spine fusions were either enhanced or retarded in order to elucidate the underlying mechanisms involved. This milestone was critical in that we now had the tools necessary to better understand how to effectively manipulate the spine fusion healing process.
II. Translation of BMP from Benchtop to Bedside
Once this groundwork was laid and the potential of BMP-2 to act as a biologic bone graft extender was realized, the next phase of BMP research at Emory focused on taking BMP-2 from the lab to the clinic. Using the now validated rabbit model of intertransverse process spinal fusion, Schimandle et al. 17) performed a series of experiments to determine the efficacy of rhBMP-2 as a potential substitute for ICBG. To do this, different dosages of rhBMP-2 loaded onto a type 1 collagen sponge were compared with the results obtained with ICBG. The authors reported that 100% of the rabbits implanted with rhBMP-2 achieved solid fusion, whereas only 42% of the autograft control fusions were solid ( Fig. 1 ). In addition, fusions achieved with rhBMP-2 were biomechanically stronger and stiffer than fusions achieved using ICBG. These results were subsequently re- confirmed in another set of experiments that were evaluated by computed tomography 18) .
Since it is difficult to extrapolate results from lower vertebrates (i.e., rabbits) to humans, a critical step in determining the viability of an osteoinductive protein like BMP for use in humans is the demonstration of its success in nonhuman primates. This is important since there are several examples of osteoinductive substances that have demonstrated good efficacy in lower vertebrates but failed to induce bone in primates 19) . As such, Martin et al. 20) examined the issues of dose, carrier, and safety when using rhBMP-2 in a rhesus monkey posterolateral intertransverse process spinal arthrodesis with or without laminectomy. The rhesus monkey was specifically chosen over other nonhuman primate species because the successful BMP dose and healing pattern are most predictive of the human response 21) . This study was the first to show the ability of rhBMP-2 to successfully form bone in nonhuman primates. In addition, the most striking findings were as follows: (1) the presence of a laminectomy defect with exposed dura did not preclude the safe use of rhBMP-2 for posterolateral fusion as there was no evidence of bone overgrowth causing impingement of the neural elements; (2) soft tissue compression of the collagen sponge carrier prevented bone induction at previously successful BMP doses, presumably due to squeezing of the protein out of the sponge; and (3) mechanical protection of the carrier from soft tissue compression allowed more bone induction at lower doses of rhBMP-2.
This landmark study not only provided important proof of feasibility for the use of rhBMP-2 in spinal arthrodesis, but it also presented an unanticipated result. Although rhBMP-2 was able to influence the local biology to achieve successful fusion, it was the carrier that was now presenting a problem in larger bipedal animals like nonhuman primates. To address this, the Emory group next set out to optimize the carrier and make it more resistant to compression from the surrounding muscle, allowing the rhBMP-2 to stay locally longer so that it could exert its intended effect.
First, we performed a set of experiments in nonhuman primates in which the authors tested a biphasic calcium phosphate (BCP) granule carrier (60% hydroxyapatite) loaded with rhBMP-2 22) . Although 100% of the spines receiving rhBMP-2 fused posterolaterally at 24 weeks, the major limitation of the carrier was its slow resorption time resulting from the high hydroxyapatite content. This made radiographic detection of new bone formation difficult. To overcome this, the authors next tested collagen sponges loaded with BCP granules and only 15% hydroxyapatite 23) . This time, a 100% fusion rate in the posterolateral spine was achieved at 24 weeks in the nonhuman primate group receiving rhBMP-2 loaded onto the new compression-resistant collagen/BCP carrier. In addition, the carrier had significantly improved radiographic resorption properties that permitted easy radiographic visualization of new bone formation. In addition, a 50% lower dose of rhBMP-2 (3 mg/side) produced consistently successful fusions (the previously used dose with the plain collagen sponge was 6 mg/side). This 100% effective dose in the posterolateral spine of nonhuman primates was then further lowered to 2 mg/side when rhBMP-2 was loaded onto an absorbable collagen sponge (ACS) wrapped around a bulking agent consisting of a BCP/ collagen composite 24) . Although the body of evidence from preclinical animal studies showed that rhBMP-2 had immense potential to enhance spinal fusion and potentially replace autologous ICBG, definitive evidence that it would work in humans was still lacking. The first definitive evidence was provided by Boden et al. 25) in the form of a prospective randomized human clinical pilot trial in which patients underwent a singlelevel ALIF using a tapered cylindrical threaded cage filled with either rhBMP-2 on an ACS or autologous ICBG. High rates of radiographic fusion (100% rhBMP-2 groups vs. 66% fusion with ICBG) and a more rapid improvement in clinical outcome were reported. This was followed by a pilot study using rhBMP-2 for posterolateral spinal fusion. Twenty-five patients were randomized to instrumented posterior fusion supplemented with ICBG or rhBMP-2 or rhBMP-2 alone without instrumentation 26) . Follow-up at a minimum of 12 months found that fusion was achieved in only 40% of the patients who received autograft, whereas 100% of the patients who were treated with BMP-2 had achieved fusion.
In the years to follow, rhBMP-2/ACS has been shown to result in significantly larger and more consistent posterolateral fusion masses: (1) in patients with degenerative spondylolisthesis when used in combination with ICBG 27) , (2) when local bone is substituted for ICBG in one-and twolevel posterolateral fusions 28) , and (3) in active cigarette smokers (95.2% successful fusion in rhBMP-2 group vs. 76.2% in ICBG group) 29) . More recently, two separate metaanalyses assessing the dose-dependent fusion rate when rhBMP-2/ACS is used in two or more level anterior cervical discectomy with fusions (ACDFs), ALIFs, transforaminal lumbar interbody fusions (TLIFs), and posterolateral fusions were performed 30, 31) . Both studies concluded that rhBMP-2 is indicated in ACDFs with two or more levels and in posterolateral fusions, but not in TLIFs. The papers reached a different conclusion regarding ALIFs. These results are summarized in Table 1 .
Despite these successes, local side effects have been reported. In a retrospective review, Cahill reported the following complications with the use of rhBMP-2 in the lumbar spine: vertebral osteolysis (44%), graft subsidence (27%) and graft migration (31%), ectopic/heterotopic bone formation (7%), and seroma/hematoma formation (3%) 32) . A concern about retrograde ejaculation has also been raised by the FDA with regard to the use of rhBMP-2 in ALIFs 33) . Similarly, systematic reviews looking at the complications associated with the use of rhBMP-2 in the cervical spine have also reported increased amounts of osteolysis and graft subsidence 32, 34) . The occurrence of most of these side effects is proportional to the dose of rhBMP-2 used. Often, the doses used in the majority of the case reports of BMP-related side effects are much higher than the recommended doses.
Despite the reported side effects, rhBMP-2 remains one of the most powerful commercially available osteogenic agents. The surgeon should reserve its use for patients in whom the risks of failed spine surgery outweigh the risks of BMP use, including older patients with osteoporosis, chronic smokers at increased risk of pseudarthrosis/delayed union, and patients undergoing revision surgery for pseudarthrosis.
III. Discovery of LMP
Despite its immense potential and ability to potently induce an osteogenic response in vivo, widespread clinical use of rhBMP-2 has been limited because of the unexpectedly high dose required in humans for consistent bone formation 15) . A 15,000-fold higher concentration of BMP-2 is required to induce bone in humans (1.5 mg/mL) than in cell culture (100 ng/mL). This need for significantly higher concentrations is at least partially because primates have a slower influx of mesenchymal stem cells and thus require higher initial loading doses of rhBMP-2 to ensure enough BMP remains by the time stem cells arrive 35) . This larger human dose (12-40 mg for one spine level) has resulted in local side effects (swelling, bone resorption, and nerve inflammation) that were not seen in preclinical studies at lower doses 25, 36, 37) . As a result, investigations at Emory were initiated to explore mechanisms by which the cellular responsiveness to BMP could be improved. It was reasoned that by increasing a cell's responsiveness, the BMP dose needed to achieve a given osteoinductive effect could be lowered, thus improving safety and cost. Using differential display polymerase chain reaction in an effort to find novel genes expressed during early osteoblast differentiation, a novel osteoinductive protein, LMP-1, was discovered 38) . Although initially discovered by treating cells with glucocorticoid, LMP-1 expression is regulated by BMP-6, which was previously shown to be stimulated by glucocorticoid and to be one of the earliest BMPs expressed during osteoblast differentiation 39) . It was subsequently shown that blocking LMP-1 expression prevented osteoblast differentiation and bone nodule formation in calvarial osteoblast cultures 40) . When LMP-1 was overex-pressed, however, osteoblast differentiation was initiated.
Unlike a BMP, which is a secreted protein that binds to a cell surface receptor to initiate a response, LMP-1 is an intracellular signaling molecule and must be located inside cells to exert its osteoinductive effect. Thus, any attempt at using LMP-1 to form bone must involve gene therapy techniques to deliver its complementary deoxyribonucleic acid (cDNA) inside the cell, resulting in the synthesis of LMP-1 protein in situ. Once the cDNA for LMP-1 was cloned and sequenced 40) , it was demonstrated in both animal and in vitro studies that a potent and consistent osteoinductive effect could be produced by delivering the LMP-1 cDNA into cells using very low doses of adenoviral or plasmid vectors 41) . To test whether these results could be extended to promoting successful posterolateral spine fusions, a proof-of-feasibility study was performed in rats 42) . After undergoing a singlelevel posterior lumbar arthrodesis, the rats received bone graft material that was soaked in cells that were transfected with either the LMP-1 cDNA or the reverse copy of the cDNA that did not express any protein. Successful spine fusion was obtained in 100% of the arthrodesis sites that received the cells transfected with the active LMP-1 cDNA, whereas none of the sites that received the inactive cDNA formed bone (0% fusion).
Although these results were very encouraging, the exact mechanism by which LMP-1 worked was still unknown. Multiple mechanistic studies were next undertaken. It was found that LMP-1 transfection caused cells both in vitro and in vivo to express elevated levels of multiple BMPs, including BMP-2, BMP-6, and BMP-7, and that this resulted in the recruitment of host cells to differentiate and participate in direct membranous bone formation in vivo 43) . It was also found that the effects of LMP-1 reinforce the action of exogenously applied BMPs and that LMP activity is blocked by the BMP inhibitor noggin 44) . Although a clear link between LMP-1 and BMP signaling had been established, the question still remained: does LMP-1 exert its effect by somehow affecting the cellular responsiveness to extracellular BMP?
The answer to this question came in 2006 when Sangadala and colleagues 45) showed that specific binding occurs between LMP-1 and Smurf1, an E3 ligase that ubiquitinates many molecules in the BMP-2 signaling pathway, which leads to their degradation by proteasomes (Fig. 2) . The authors demonstrated that LMP-1 works by competing with Smad1 and Smad5 for Smurf1 binding, thereby enhancing cellular responsiveness to exogenous BMP-2 by preventing the degradation of these key intracellular signaling molecules in the BMP pathway. The authors also showed that the LMP-1/Smurf1 interaction requires the Smurf1 WW2 domain, which is dependent on a specific motif in LMP-1, and that LMP-1's biologic effects on BMP responsiveness can be mimicked by a small peptide containing only that motif.
This was the first study to show that the cellular responsiveness to BMP could in fact be modulated via regulation of Smad degeneration. It was becoming clear that the use of LMP-1 was a potential viable strategy to reduce the BMP-2 dose needed in humans to achieve successful spine fusion in an attempt to limit the financial cost and local side effects that were being seen with the high doses being used clinically. The issue of delivery remained, however, since LMP-1 is only an intracellular protein with no extracellular receptors to interact with. Since gene therapy in humans is still not widely accepted due to the potential risks 46) , alternative strategies were investigated. These included the engineering and cloning of a recombinant LMP-1 containing an Nterminal HIV-derived membrane transduction domain called TAT, which conveys the ability to cross cell membranes. In fact, it was demonstrated that fusing the TAT motif to LMP-1 indeed allowed LMP-1 to cross the cell membrane and exert its usual intracellular effects in vitro 47) . Although being able to deliver extracellular LMP-1 without gene therapy techniques was an exciting result 47) , this strategy did not adequately address the restrictive high cost and large-scale manufacturing problems associated with recombinant proteins. Thus, the Emory group decided to build on everything that they had learned from their years of BMP and LMP-1 research and focus on designing osteoinductive small molecule drugs that could potentially activate the BMP signaling cascade.
IV. Small Molecule Design
In contrast to full-sized recombinant proteins like BMP-2 and LMP-1, small molecules have several important advantages: (1) they have significantly cheaper manufacturing cost, (2) greater stability and far superior shelf life, and (3) easier engineering and incorporation into carriers to achieve controlled spatial and temporal release. In addition, their relatively small size compared with recombinant proteins affords them immunoprivilege 48) . These factors significantly increase the attractiveness of using pharmacologic small molecules over recombinant protein strategies in the spine.
Although multiple negative regulators of the BMP signaling pathway have been identified, LMP-1 is unique in that it represents a rare positive regulator of BMP signaling and thus is an attractive target for small molecule drugs. Since it was already known that Smurf1 interaction with LMP-1 is based on the presence of a unique WW2 domain-interacting motif 45) , site-directed mutagenesis and binding studies on purified recombinant proteins was performed 49) in order to find the specific WW-interacting motif within the osteogenic region of LMP-1 that binds to this WW2 domain on Smurf1. Computational, homology-based modeling of the LMP-1/ Smurf1 interaction was performed in silico, and the key amino acids involved in their binding regions were identified (Fig. 3) . This knowledge was paramount in the design of effective mimetic compounds that could either mimic or disrupt this specific interaction.
In order to screen large numbers of potential candidate compounds, the Emory group next developed and optimized a cell-based assay to use as a tool to identify reagents that 50) developed a new gene expressionbased cell monitoring approach that selects reagents based on their real effects on cell physiology. This novel cellbased assay was successfully used to screen for active compounds from a select group of compounds that were identified by computational screenings as the most likely candidates for mimicking the function of LMP-1. One particular compound, SVAK-3, showed a dose-dependent potentiation of BMP-2 activity by inducing osteoblastic transdifferentiation of myoblastic C2C12 cells 50) . Although SVAK-3 at first seemed to be a great candidate for a clinically translatable small molecule drug, it was unfortunately found to be rather unstable and quickly lost its biologic activity in vivo. This warranted a new search for a more stable and efficacious compound. First, Kato and colleagues 51) performed extensive chemo-informatic in silico analyses of the Smurf1 WW2 domain and its interacting site with LMP-1 on over 70,000 small molecules with known drug-like capabilities (Fig. 4 ). The authors next tested those leading candidates in their cell-based screening assay using a Smad1-specific luciferase reporter. A unique compound called SVAK-12 was identified and was found to be more stable than SVAK-3 as well as promote the BMP-induced expression of phenotypic markers characteristic of a differentiated osteoblast in a dose-dependent manner.
The small synthetic molecule SVAK-12 was further tested for its ability to enhance bone formation in vivo 52) . Specifically, it was tested for its ability to enhance bone formation of a suboptimal dose of rhBMP-2 in a rodent ectopic model and to test whether a single percutaneous injection of SVAK-12 could accelerate callus formation in a rodent femoral fracture model. In the ectopic model, SVAK-12 produced a dose-dependent enhancement of rhBMP-2 activity (Fig. 5) . SVAK-12 also resulted in significantly higher fracture healing rates in the femoral fracture model as well as better radiographic healing scores and biomechanical testing results (i.e., 43% stronger and 93% stiffer). This landmark study showed for the first time that a single dose of a small molecule drug administered subcutaneously could enhance bone healing by increasing the cellular responsiveness to both exogenous rhBMP-2 (ectopic model) and endogenous BMPs (femoral fracture model).
Since this study, the Emory group has continued to work on discovering, characterizing, and testing both novel and FDA-repurposed small molecule drugs to enhance bone formation. We have worked on producing small molecules that target Jab1 53) , which targets a common Smad, Smad4, shared by both the BMP and transforming growth factor-β (TGF-β) pathways, for proteasomal degradation. Jab1 also binds to Smad4, Smad5, and Smad7, key intracellular signaling molecules of the TGF-β superfamily, and causes ubiquitination and/or degradation of these Smads as well. In addition to Jab1, our lab has also more recently developed small molecule drugs that inhibit the function of Noggin, a BMP antagonist, as well as a small molecule that binds directly to the sclerostin receptor, LRP-5/6. This sclerostin small molecule inhibitor has been shown in our lab to enhance both BMP and canonical Wnt signaling in vitro and in vivo (unpublished data).
Conclusion
Careful consideration must be given to the eventual biologic goal of a spinal arthrodesis: successful bone formation and fusion. Bone is the material that, for a lifetime, will bear the stresses that instrumentation can support only temporarily. Over 25 years of translational spine and BMPrelated research here at Emory has been dedicated toward advancing our knowledge of how to use biologics to enhance bone formation and achieve consistently reliable spinal fusions. Our lab continues to work on testing multiple candidate small molecule drugs in translational models, and we remain confident that the local application of osteogenic small molecules has the potential to lower the required doses of rhBMP used clinically and might someday decrease their cost, improve their safety profile, and allow for their more widespread routine use.
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